EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Targeting mineralocorticoid receptors to treat metabolic diseases via the adipocyte

Andrea Armani, Stefania Gorini, Alessandra Feraco, Caterina Mammi, Eleonora Bellucci, Massimiliano Caprio iD

Endocrinology · 2026

DOI: 10.1210/endocr/bqag004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology, 2026. Verfasst von Andrea Armani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department for the Promotion of Human Sciences and Quality of Life, San Raffaele Roma Open University, Rome 00166, Italy. Hauptthemen laut MEDLINE: Receptors, Mineralocorticoid, Mineralocorticoid Receptor Antagonists, Adipocytes, Metabolic Diseases. Gefördert von: Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The mineralocorticoid receptor (MR), classically known for its role in electrolyte homeostasis, has emerged since the early 2000s as a key regulator of adipocyte biology. MR activation induces oxidative stress and inflammation, promotes white adipogenesis, and suppresses brown fat differentiation, potentially contributing to obesity and metabolic syndrome (MetS). In mice, MR antagonists (MRAs) have shown beneficial metabolic effects by reversing adipose tissue dysfunctions, counteracting excessive expansion of fat depots and enhancing brown adipose tissue (BAT) thermogenesis. Clinical translation remains limited, with inconsistent outcomes in individuals with overweight or obesity, and concerns about side effects of steroidal MRAs (sMRAs), particularly hyperkalemia. Nevertheless, recent data showed that MRAs are able to activate BAT in healthy subjects and in patients with familial partial lipodystrophy type 2 (FPLD2). Nonsteroidal MR antagonists (nsMRAs), such as finerenone, exhibit anti-inflammatory and anti-fibrotic properties in the kidney and heart, with improved safety profiles compared to steroidal MR antagonists (sMRAs), and are currently explored in metabolic disorders beyond cardiorenal disease. This review summarizes novel insights into MR function in adipose tissue and critically evaluates whether MR can still be considered a valid target to treat obesity and associated metabolic disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, MineralocorticoidMineralocorticoid Receptor AntagonistsAdipocytesMetabolic DiseasesHumansAnimalsObesityAdipose Tissue, BrownMetabolic Syndrome

Stichwörter der Autor:innen

adipose tissuealdosteronebrown fatmetabolic syndromemineralocorticoid receptor antagonist

Substanzen

Receptors, MineralocorticoidMineralocorticoid Receptor Antagonists

Autor:innen und Institutionen

  • Department for the Promotion of Human Sciences and Quality of Life, San Raffaele Roma Open University, Rome 00166, Italy.
  • Laboratory of Cardiovascular Endocrinology, IRCCS San Raffaele, Rome 00166, Italy.

ORCID-Profile: Massimiliano Caprio

Förderung

  • Italian Ministry of Health

Zitieren

APA

Armani, A., Gorini, S., Feraco, A., Mammi, C., Bellucci, E., & Caprio, M. (2026). Targeting mineralocorticoid receptors to treat metabolic diseases via the adipocyte. Endocrinology. https://doi.org/10.1210/endocr/bqag004

Vancouver

Armani A, Gorini S, Feraco A, Mammi C, Bellucci E, Caprio M. Targeting mineralocorticoid receptors to treat metabolic diseases via the adipocyte. Endocrinology. 2026. doi:10.1210/endocr/bqag004

BibTeX
@article{Armani2026,
  author = {Armani, Andrea and Gorini, Stefania and Feraco, Alessandra and Mammi, Caterina and Bellucci, Eleonora and Caprio, Massimiliano},
  title = {Targeting mineralocorticoid receptors to treat metabolic diseases via the adipocyte},
  journal = {Endocrinology},
  year = {2026},
  doi = {10.1210/endocr/bqag004}
}
Kostenlos starten →